Ginkgo Bioworks Holdings annual cash and equivalents
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings Cash & Equivalents Growth & History (DNA)
Ginkgo Bioworks Holdings's cash and equivalents was $167.2M for fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $167.2M | −$394.4M | −70.23% |
| 2024 | 2024-12-31 | $561.6M | −$382.5M | −40.52% |
| 2023 | 2023-12-31 | $944.1M | −$371.7M | −28.25% |
| 2022 | 2022-12-31 | $1.32B | −$234.2M | −15.11% |
| 2021 | 2021-12-31 | $1.55B | $1.17B | +307.04% |
| 2020 | 2020-12-31 | $380.8M | −$114.5M | −23.12% |
| 2019 | 2019-12-31 | $495.3M | — | — |
Ginkgo Bioworks Holdings quarterly cash and equivalents
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $84.5M | −$119.0M | −58.47% |
| Q1 2026 | 2026-03-31 | $143.9M | −$168.6M | −53.95% |
| Q4 2025 | 2025-12-31 | $167.2M | −$394.4M | −70.23% |
| Q3 2025 | 2025-09-30 | $111.1M | −$505.1M | −81.98% |
| Q2 2025 | 2025-06-30 | $203.6M | −$526.8M | −72.13% |
| Q1 2025 | 2025-03-31 | $312.4M | −$528.0M | −62.83% |
| Q4 2024 | 2024-12-31 | $561.6M | −$382.5M | −40.52% |
| Q3 2024 | 2024-09-30 | $616.2M | −$433.0M | −41.27% |
| Q2 2024 | 2024-06-30 | $730.4M | −$375.4M | −33.95% |
| Q1 2024 | 2024-03-31 | $840.4M | −$365.6M | −30.32% |
| Q4 2023 | 2023-12-31 | $944.1M | −$371.7M | −28.25% |
| Q3 2023 | 2023-09-30 | $1.05B | −$253.4M | −19.45% |
| Q2 2023 | 2023-06-30 | $1.11B | −$271.4M | −19.70% |
| Q1 2023 | 2023-03-31 | $1.21B | −$286.9M | −19.22% |
| Q4 2022 | 2022-12-31 | $1.32B | −$234.2M | −15.11% |
| Q3 2022 | 2022-09-30 | $1.30B | −$436.5M | −25.10% |
| Q2 2022 | 2022-06-30 | $1.38B | $1.14B | +483.80% |
| Q1 2022 | 2022-03-31 | $1.49B | $1.18B | +384.53% |
| Q4 2021 | 2021-12-31 | $1.55B | $1.55B | — |
| Q3 2021 | 2021-09-30 | $1.74B | — | — |
| Q2 2021 | 2021-06-30 | $235.9M | — | — |
| Q1 2021 | 2021-03-31 | $308.1M | — | — |
| Q4 2020 | 2020-12-31 | $0 | — | — |
Ginkgo Bioworks Holdings cash and equivalents trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's cash and equivalents decreased from $380.8M to $167.2M, a change of −$213.6M. The latest reported quarter, Q2 2026, shows $84.5M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...